---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-248242"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-05-29T20:05:14+00:00"
generated_at: "2026-05-29T20:08:58.004758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acadia shareholders approve 5.2M-share increase to 2024 equity plan, re-elect three Class I directors

## Summary
- Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.
- Re-elected Class I directors James M. Daly, Edmund P. Harrigan, and Adora Ndu to Board until 2029.
- Advisory vote on executive compensation approved with 98.7% of votes cast in favor.
- Ernst & Young ratified as independent auditor for FY2026 with 157,409,378 votes for.

## SEC filing metadata
- accession: 0001193125-26-248242
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-05-29T20:05:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/0001193125-26-248242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/d140910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-248242
- JSON: https://secwatch.observer/filing/0001193125-26-248242.json
- Plain text: https://secwatch.observer/filing/0001193125-26-248242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.